Introduction
Renal glucose production increases with insulin resistance, the hallmark of type 2 diabetes (T2D). 1 Approximately 40% of the increased endogenous glucose release in patients with T2D has been attributed to renal gluconeogenesis. 1 Furthermore, the capacity for renal glucose reabsorption is higher in patients with T2D, thus perpetuating hyperglycemia. 2 SGLT2 is located in the proximal tubule and is involved in the reabsorption of glucose (~90%) in the kidney. 3 As the action of SGLT2 is independent of insulin, its inhibition should not be influenced by the degree of insulin resistance or insulin secretion. 4 Therefore, SGLT2 inhibitors have the potential to be effective in reducing hyperglycemia by stimulating urinary glucose excretion at any stage and duration of T2D. In 2015, the 
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Scheerer et al American Diabetes Association and European Association for the Study of Diabetes issued an update to their joint position statement on the management of hyperglycemia in T2D. 5 SGLT2 inhibitors are mentioned among the options for secondline therapy after treatment with metformin and as alternative first-line options in patients with contraindications to metformin in an oral triple therapy or as add-on to insulin therapy. 5 Dapagliflozin was the first approved selective SGLT2 inhibitor in Europe that reduces hyperglycemia through the reduction of glucose reabsorption into the kidney. 6 Previous randomized clinical studies on dapagliflozin have demonstrated reductions in glycated hemoglobin (HbA1c) at all stages of T2D progression, favorable effects on body weight (BW), and a moderate lowering of blood pressure. These benefits have been observed when dapagliflozin was used as monotherapy or in combination with metformin (normal and extended release formulations), sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, or insulin. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, there is a paucity of data on the efficacy of dapagliflozin in a real-world setting, eg, in primary care patients with T2D. Furthermore, studies to determine baseline characteristics that could be used to predict which patients would benefit most from dapagliflozin treatment are lacking.
The first aim of this study was to investigate changes in treatment outcomes (HbA1c, BW, systolic blood pressure [SBP]) for T2D patients initiating dapagliflozin therapy using a large database representative of practices in Germany. The second aim was to evaluate baseline clinical predictors of changes in HbA1c, weight, and SBP after dapagliflozin initiation.
Methods
The Disease Analyzer database (IMS Health GmbH & Co. OHG) collects drug prescriptions, diagnoses, and basic medical and demographic data directly obtained from the computer system of a representative sample of general practitioners and internal medicine practices throughout Germany. 17 For such studies based on anonymous data in Germany no special ethic approval or patient consent is required and hence it was not sought for this study. The analyzed database period for the current study was from December 2012 to October 2014 (985 general and 32 diabetologist practices). Patients with T2D who were initiated on dapagliflozin therapy during the study period (index date) were included. Two cohorts with ≥3-or ≥6-month follow-up after index date were analyzed, respectively. The practice visit records were used to determine baseline demographic characteristics 6 months prior to the index date.
Macrovascular complications were determined based on primary care diagnoses (ICD-10 codes) for coronary heart disease (I24, I25), myocardial infarction (I21, I22, I23, I25.2),  stroke (I63, I64, G45), and peripheral vascular disease (I739,  E105, E115, E145). Microvascular complications included  retinopathy (E113, E143, H360), neuropathy (E114, E144) , and nephropathy (N18, N19, E112, E142, Z49, Z992). Treatment with antidiabetic drugs prior to the index date was also assessed. Finally, the recorded HbA1c values and the documented BW and SBP before and after the index date were included in the analyses.
Descriptive statistics were provided and changes in HbA1c, BW, and blood pressure were assessed using paired t-tests. Two-sided tests were used and a P-value of <0.05 was considered as statistically significant. Scatter plots were used to visualize changes in BW and changes in HbA1c. Multivariate linear regression model was fitted to investigate the associations between clinical variables or comorbidity and changes in HbA1c, BW, and SBP, respectively. All analyses were carried out in accordance with the Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations of the German Society 18 using SAS 9.3 (SAS Institute, Cary, NC, USA).
Results
Upon patient selection, 1,169 new users of dapagliflozin (age: 62.5 years; male: 59.3%) were included. The baseline clinical characteristics are shown in Table 1 . Approximately 25% of the T2D patients who received dapagliflozin were treated by diabetologists. There was a high prevalence of privately insured patients. Approximately 10% of the patients received dapagliflozin monotherapy, whereas biguanides were the antidiabetic drug most frequently prescribed in combination with dapagliflozin, followed by insulin (Table 1) .
Macrovascular complications and related risk factors were frequently found in the T2D patients initiating dapagliflozin therapy (Table 1) . Coronary heart disease, peripheral vascular disease, history of myocardial infarction, or stroke was diagnosed in 47% of the patients prior to onset of dapagliflozin treatment. Microvascular diabetes complications were observed in 22% of the study population (Table 1) .
At 3 months, a statistically significant reduction in mean HbA1c from baseline (8.5%) was observed with dapagliflozin (−0.8%) (P<0.001) ( Table 2 ). The reduction in HbA1c with dapagliflozin treatment was maintained at 6 months (−0.8%: standard deviation [SD]: 1.4) (P<0.001) ( Table 3 ). Greater HbA1c decreases were observed with dapagliflozin in 466 patients with higher baseline HbA1c >8.0% (−1.3%; SD: 1.5) (P<0.001) and 251 patients with 
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Dapagliflozin effects on HbA1c, weight, and blood pressure P<0.05) ( Tables 2 and 3 ). The effects of dapagliflozin on HbA1c and BW were largely comparable in both T2D patients treated in general practices and diabetologist care (Tables 2  and 3 ). The reductions in SBP at both 3 and 6 months were somewhat greater in patients treated by diabetologists compared to patients in general practices.
Scatter plots representing the relationship between reductions in HbA1c and BW after 3 and 6 months of treatment are shown in Figures 1 and 2 , respectively. Approximately 50% of patients receiving dapagliflozin responded simultaneously to the two-item endpoint of combined HbA1c (>0% HbA1c%) and BW (>0 kg) reductions at 3 months ( Figure 1 ). The combined endpoint reductions were achieved in 45% of new dapagliflozin patients after 6 months ( Figure 2 ). Furthermore, ~19% of patients treated with dapagliflozin achieved an HbA1c reduction at 3 months despite an increase in BW (Figure 1 ). At 6 months, this proportion increased to 25% ( Figure 2 ). After 3 months of dapagliflozin treatment, only 8.5% failed to exhibit reductions in both HbA1c and BW. After 6 months, the corresponding proportion was 12.4%.
The correlations of baseline clinical variables with changes in HbA1c after onset of dapagliflozin treatment were investigated using linear regression. Only baseline HbA1c was statistically significantly inversely related to change in HbA1c after both 3 and 6 months, indicating that higher HbA1c values were related to a greater decrease after onset of dapagliflozin treatment (P<0.0001). Furthermore, age was positively correlated with the HbA1c decrease observed at 3 months, indicating that HbA1c increased with age after the index date (Table 4) . Finally, diabetologist treatment >9.0% (−1.8%; SD: 1.7) (P<0.001) at 3 months, and these greater reductions were still evident at 6 months (data not shown).
A statistically significant reduction in mean BW was observed in patients treated with dapagliflozin at 3 months (−2.3 kg) ( Table 2) and was maintained through 6 months (−2.5 kg) ( 
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Scheerer et al was related to a significantly greater decrease in HbA1c at 6 months compared to treatment in general practices.
Baseline BW was inversely related to weight change (kg) both at 3 and 6 months, indicating that higher BW was related to a greater change after onset of dapagliflozin treatment (Table 5) . Furthermore, diabetologist care was related to a greater weight change at 3 months after onset of dapagliflozin therapy compared to treatment in general practices.
With respect to changes in SBP at 3 months, only baseline systolic values (negative) and age (positive) were statistically significantly related (data not shown). Thus, higher baseline SBP was related to a greater decrease. At 6 months, only baseline SBP was negatively related to its change; this change was statistically significant.
Changes in HbA1c, BW, and SBP in various subgroups of patients treated with antidiabetic combination therapies, including dapagliflozin, are shown in Tables S1 and S2. After 3 months of treatment, both dapagliflozin monotherapy and combination therapy with metformin, insulin, or DPP-4 inhibitors yielded statistically significant decreases of HbA1c 
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Dapagliflozin effects on HbA1c, weight, and blood pressure and BW (Table S1) . A statistically significant reduction of SBP was also observed in patients treated with dapagliflozin and DPP-4 inhibitors. After 6 months of treatment, similar statistically significant reductions of HbA1c and BW were found for dapagliflozin monotherapy (Table S2) . Moreover, a statistically significant decrease in HbA1c and BW was observed for dapagliflozin combination therapy with insulin or DPP-4 inhibitors. A statistically significant HbA1c reduction was maintained in patients with dual treatment with metformin, whereas a borderline statistical significance was found for BW (P=0.06). With respect to SBP, no statistically significant decrease was observed in all four treatment subgroups after 6 months of treatment. However, patient numbers are small in several of these groups, thus limiting statistical power.
Discussion
For the first time, a real-world study evaluated the shortterm changes in HbA1c, BW, and SBP in T2D patients initiating dapagliflozin treatment in primary care and 
Changes in HbA1c
In the dapagliflozin clinical trial program, monotherapy yielded a statistically significant HbA1c reduction of 0.66% after 24 weeks when compared to placebo (−0.89% vs −0.23%, P<0.0001). 7 As an add-on to metformin, dapagliflozin consistently improved HbA1c (placebo-corrected) by 0.54% after 24 weeks (−0.84% vs −0.30%, P<0.0001). 8 In third-line therapy, when dapagliflozin was used concomitant with the DPP-4 inhibitors sitagliptin or saxagliptin, HbA1c reductions of −0.5% (−0.5% vs 0.0%, P<0.0001) and −0.72% (−0.82% vs 0.10%, P<0.0001), respectively, were observed compared with placebo after 24 weeks. 10, 16 In third-line therapy with metformin and sulfonylureas, dapagliflozin led to placebo-corrected HbA1c reductions of −0.69% (P<0.0001). 15 Moreover, addition of dapagliflozin in T2D patients receiving high doses of insulin (≥30 IU/day) and up to two other antidiabetic agents effectively reduced HbA1c by 0.57% compared with placebo after 24 weeks (−0.96 vs −0.39%, P<0.001) 11 and by 0.35% over a period of 2 years (−0.78% vs −0.43%, P<0.0007) with stable insulin doses over the entire study period and a net increase of placebo by 19.2 IU at 2 years when compared to the study drug. 19 In the present study, the HbA1c reduction of 0.8% achieved with dapagliflozin after 3 and 6 months was commensurate with most HbA1c reductions over 24 weeks found in the dapagliflozin arm of clinical trials, rather than their placebo-corrected margin.
Similar results were obtained for the second largest cohort of patients using dapagliflozin as an add-on to insulin (33%). This cohort exhibited an HbA1c reduction of 0.8% after 6 months. Identical numerical reduction of HbA1c at 6 months was shown for the oral triple therapy adding dapagliflozin to a preexisting treatment with metformin and a DPP-4 inhibitor. This observation in real-life yielded reductions similar to the recently published clinical trial using dapagliflozin as a thirdline drug add-on to metformin and saxagliptin. 16 This analysis also indicated clinical variables that are independently related to change in HbA1c after initiation of dapagliflozin treatment. Most important, the baseline HbA1c was inversely related to both the changes in HbA1c at 3 and 6 months. This result is in accordance with a recent clinical trial with statistically significantly greater HbA1c reductions observed with dapagliflozin treatment in patients with baseline HbA1c ≥8.0% (−0.56%) and ≥9.0% (−0.99%) at 6 months compared to the overall sample (−0.46%). 20 In this real-world study, a greater HbA1c reduction was found in patients treated in diabetologist practices. This outcome most likely reflects the fact that diabetologists are more familiar with the relatively new dapagliflozin therapy. The positive correlation with age found in the present study ostensibly indicates that older patients have a more advanced stage of the disease along with declining kidney function, which makes it more difficult to achieve a reduction in HbA1c using dapagliflozin.
Taken together, dapagliflozin usage in real life favorably reflected the HbA1c reductions previously measured in the 
Changes in body weight
The weight loss observed in the present study was consistent with the weight loss observed across RCTs in clinical trials. 21 Twelve RCTs, including 2,005 participants in the intervention groups and 2,003 participants in the control groups with follow-up durations ranging from 12 to 104 weeks, were included in a meta-analysis. 21 BW decreases ranged from −3.33 to −1.54 kg after treatment with dapagliflozin. 21 The overall mean difference between the intervention and control groups was −2.10 kg (P<0.001). 21 In another network metaanalysis of RCTs, the mean change in weight associated with dapagliflozin was statistically significant compared with the other antidiabetic agents: −2.74 kg relative to DPP-4 inhibitors, and −4.67 kg relative to sulfonylureas. 22 The results from the present real-world study demonstrate that similar reductions in BW (−2.5 kg at 6 months) can be achieved in primary care patients. This weight loss has been attributed to the ~200-300 cal of glucose excreted per day as a result of treatment with dapagliflozin. 23 Although the impact of this amount of weight loss on mortality and cardiovascular events is debatable, even small weight decreases in T2D have been shown to improve treatment satisfaction and quality of life. 24, 25 Similar to HbA1c, baseline BW was negatively correlated with weight change at 3 months. The BW reduction observed in clinical trials for dapagliflozin was primarily caused by a reduction in body fat mass, as shown by dual energy X-ray absorptiometry and calorie loss. 26 A subgroup analysis using magnetic resonance imaging showed a reduction of visceral adipose tissue mass greater than 9% compared to the baseline during treatment with dapagliflozin. Furthermore, consistent with the changes in HbA1c, diabetologist care was associated with a greater change in BW at 3 months. This most likely reflects more intensive care and/or a more motivated patient population.
Changes in systolic blood pressure
A recent meta-analysis of 27 RCTs involving dapagliflozin (n=12) reported that SGLT2 inhibitor use was associated with a statistically significant reduction in SBP from baseline (−4.0 mmHg). 27 This real-world study also showed statistically significant reductions in SBP (−2.3 mmHg) at 6 months. The impact of the blood pressure reductions achieved with dapagliflozin on cardiovascular outcomes requires further investigation. The underlying mechanisms of a dapagliflozin-specific reduction of SBP must be identified. In the present investigation, baseline blood pressure (inverse association) was the only relevant variable associated with changes in SBP.
Strength and limitations of the study
The present study provides an illustration of prescriptions and diagnoses in primary care and diabetologist practices in Germany. The strength of the study is the use of a large nationwide database and the unbiased assessment of prescriptions and outcomes. As this study used primary care records, a number of limitations should be mentioned: First, no valid information regarding onset of diabetes was provided. Additionally, assessment of comorbidities solely relied on ICD codes filled in by physicians. Moreover, measurements of HbA1c and body mass index values were not standardized. Finally, data on socioeconomic status and lifestyle-related risk factors were also unavailable. It must also be mentioned that, in this study, the adherence to the dapagliflozin administration was not assessed. No investigation was also performed about the change of other antihyperglycemic drugs during the study period. Both adherence and therapy change might affect the findings.
Conclusion
This is the first report of real-world outcomes concerning the effect of dapagliflozin on HbA1c, BW, and systolic blood pressure in T2D patients in primary care and diabetologist practices. The absolute reductions in HbA1c (−0.8%), BW (−2.5 kg), and SBP (−2.3 mmHg) observed in patients inadequately controlled with other antidiabetic agents and insulin were similar to results from the dapagliflozin clinical trial program.
